{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:27:19Z","timestamp":1783744039512,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.vaccine.2021.09.021","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T06:10:14Z","timestamp":1643609414000},"page":"1370-1375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity of meningococcal polysaccharide conjugate vaccine as a replacement for meningococcal polysaccharide vaccine in children in Guangzhou, China"],"prefix":"10.1016","volume":"40","author":[{"given":"Qing","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhencui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangxiong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhoubin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.vaccine.2021.09.021_b0005","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1056\/NEJMcp063561","article-title":"Clinical practice. Prevention of meningococcal disease","volume":"355","author":"Gardner","year":"2006","journal-title":"N Engl J Med"},{"issue":"05","key":"10.1016\/j.vaccine.2021.09.021_b0010","first-page":"481","article-title":"Epidemiological characteristics of meningococcal meningitis and switching trend of serogroups of Neisseria meningitidis in China","volume":"21","author":"Li","year":"2015","journal-title":"Chin J Vaccine Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.021_b0015","doi-asserted-by":"crossref","first-page":"20409","DOI":"10.7189\/jogh.06.020409","article-title":"Burden of Neisseria meningitidis infections in China: a systematic review and meta-analysis","volume":"6","author":"Zhang","year":"2016","journal-title":"J Glob Health"},{"issue":"5","key":"10.1016\/j.vaccine.2021.09.021_b0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jinf.2018.01.007","article-title":"Meningococcal disease and control in China: Findings and updates from the Global Meningococcal Initiative (GMI)","volume":"76","author":"Li","year":"2018","journal-title":"J Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2021.09.021_b0025","first-page":"159","article-title":"Analysis of epidemic characteristics for meningococcal meningitis in China during 2015\u20132017","volume":"53","author":"Li","year":"2019","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.vaccine.2021.09.021_b0030","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s12879-018-3422-0","article-title":"The landscape of vaccines in China: history, classification, supply, and price","volume":"18","author":"Zheng","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2021.09.021_b0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/vaccines7030097","article-title":"Procurement of Category 2 Vaccines in China","volume":"7","author":"Zhuang","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2021.09.021_b0040","first-page":"1","article-title":"Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"Morbidity and Mortality Weekly Report (MMWR)"},{"key":"10.1016\/j.vaccine.2021.09.021_b0045","unstructured":"Plotkin S, Orenstein W, Offit P, Edwards KM. VACCINES: Elsevier, 2017."},{"key":"10.1016\/j.vaccine.2021.09.021_b0050","unstructured":"Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 2011;86(47):521-39."},{"issue":"12","key":"10.1016\/j.vaccine.2021.09.021_b0055","first-page":"1241","article-title":"Immunogenicity and Immune Persistence Study of Group A and C meningococcal polysaccharide vaccine in children aged between 2\u20136 years in Guangdong Province","volume":"41","author":"Fan","year":"2020","journal-title":"Guangdong Medical J"},{"issue":"8","key":"10.1016\/j.vaccine.2021.09.021_b0060","first-page":"878","article-title":"Safety and Immunogenicity of Groups A+C Meningococcal Conjugate. Chinese","volume":"23","author":"Shi","year":"2010","journal-title":"J Biologicals"},{"issue":"10","key":"10.1016\/j.vaccine.2021.09.021_b0065","first-page":"920","article-title":"Evaluation of safety of meningococcal group AC bivalent polysaccharide conjugate vaccine in children aged 5\u201324 months","volume":"47","author":"Zhou","year":"2013","journal-title":"Chinese J Preventive Med"},{"issue":"12","key":"10.1016\/j.vaccine.2021.09.021_b0070","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1080\/21645515.2019.1627816","article-title":"Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT): two immune schedules in toddles aged 12\u201323 months in China","volume":"15","author":"Hu","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2021.09.021_b0075","first-page":"123","article-title":"Experts\u2019 consensus on immunization with meningococcal vaccines in China","volume":"02","year":"2019","journal-title":"Chin J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.09.021_b0085","first-page":"37","article-title":"Observation on the Safety and Immunogenicity of Group A\/C Meningococcal Conjugate Vaccine","volume":"01","author":"Zhou","year":"2008","journal-title":"Chinese J Vaccine Immunization"},{"issue":"05","key":"10.1016\/j.vaccine.2021.09.021_b0090","first-page":"765","article-title":"Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine in 3-month \u2013 5-year old children: a phase III, single-center, randomized controlled trial","volume":"36","author":"Hu","year":"2020","journal-title":"Chin J Public Health"},{"issue":"03","key":"10.1016\/j.vaccine.2021.09.021_b0095","first-page":"297","article-title":"Immunogenicity and safty of freeze-dried groups A and C meningococcal polysaccharide conjugate vaccine in healthy infants at ages of 3\u20138 months","volume":"33","author":"Shi","year":"2020","journal-title":"Chin J Biologicals"},{"issue":"08","key":"10.1016\/j.vaccine.2021.09.021_b0100","first-page":"737","article-title":"Immunogenicity of groups A and C meningococcal polysaccharide conjugate vaccine","volume":"48","author":"Zhou","year":"2014","journal-title":"Chin J Prev Med"},{"issue":"03","key":"10.1016\/j.vaccine.2021.09.021_b0105","first-page":"245","article-title":"Immunogenicity and persistence of immunity following a booster of group A and group C meningococcal polysaccharide vaccine among children who had received primary vaccination with group A and group C meningococcal polysaccharide conjugate vaccine","volume":"26","author":"Tang","year":"2020","journal-title":"Chinese J Vaccines Immunization"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2021.09.021_b0110","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:09:39Z","timestamp":1759403379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21012007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0264410X21012007"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of meningococcal polysaccharide conjugate vaccine as a replacement for meningococcal polysaccharide vaccine in children in Guangzhou, China","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}